Articles related to GENETIC TESTING

Talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% versus enzalutamide alone in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations, with a 3-year rPFS rate of 77% versus 56% in a 599-patient phase 3 trial.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.

A 23-year-old woman with bilateral blurry vision, floaters, and a history of premature birth presented with exudative retinopathy and vascular features overlapping multiple inherited and acquired retinal disorders.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

A 55-year-old man with bilateral hand arthritis, ruddy complexion, and elevated transferrin saturation presents a diagnostic reasoning challenge with implications for screening, surveillance, and family testing.